

SKYEPHARMA PLC
Form 6-K
February 08, 2007

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

SkyePharma PLC

Announces Results of Shareholder Vote

LONDON, UK, 8 February 2007 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces the results of its Extraordinary General Meeting held earlier today.

All of the resolutions proposed were passed:

- o Approval of the proposed sale of the Injectable Business to Blue Acquisition Corp (the "Disposal")
- o Authorisation of the Directors to allot the new Ordinary Shares in connection with the Disposal and the expenses thereof
- o Disapplication of statutory pre-emption rights in relation to the Placing

Good progress is being made with completing the various other conditions for the Disposal. The Directors have jointly concluded that the transaction is not subject to the notice provisions of the Hart-Scott-Rodino Act of 1976 ("HSR") and that there are no HSR conditions applicable with respect to the Closing. The necessary consents, which are subject to approval from Paul Capital's financial guaranty insurer and not expected to be received shortly. It is expected that, once these agreements and consents are in place, the Disposal, which is conditional upon the Disposal being completed, will take place on the stock market trading on the completion. A further announcement will be made when the Disposal is completed.

Forthcoming results announcement

The announcement of the full year audited results for 2006 is scheduled to take place on 26 April 2007.

Frank Condella, SkyePharma's Chief Executive, said:

"I would like to thank shareholders for their support in passing these resolutions. Following the Disposal, SkyePharma is well funded and in a good position to build future value by further developing key products and technologies."

For further information please contact:

SkyePharma PLC

Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director

+44

Buchanan Communications

Tim Anderson / Mark Court / Rebecca Skye Dietrich

+44

Trout Group (US)

Seth Lewis

+

Notes for editors

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies and more effective drug formulations. The continuing business has nine approved products incorporated into the areas of oral, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, please visit www.skyepharma.com.

These materials are not an offer for sale of securities in the United States. The securities described herein have not been registered under the US Securities Act of 1933 (the "Securities Act") and the securities may not be sold in the United States in the absence of registration or an exemption from registration under the Securities Act. The Company does not intend to register these securities under the Securities Act.

Edgar Filing: SKYEPHARMA PLC - Form 6-K

of such offering in the United States or to conduct a public offering of the ordinary shares in t

The information contained herein does not constitute an offer to sell or the solicitation of sale of the securities referred to herein in any jurisdiction in which such offer, sollicitati registration, exemption from registration or qualification under the securities laws of any juris

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ John Murphy

Name: John Murphy
Title: Company Secretary

Date: February 8, 2007